SC
RLAY icon

Sessa Capital’s Relay Therapeutics RLAY Stock Holding History

Sessa Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-301,200
Closed -$4.5M – 48
2022
Q4 		$4.5M Hold
301,200
– – 0.28% 27
2022
Q3 		$6.74M Hold
301,200
– – 0.48% 22
2022
Q2 		$5.04M Hold
301,200
– – 0.28% 26
2022
Q1 		$9.02M Buy
+301,200
New +$7.31M 0.43% 26

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sessa Capital's RLAY Position: Q1 2023 in Review

Sessa Capital sold out of Relay Therapeutics (RLAY) in Q1 2023, closing a stake of 301,200 shares — an estimated $4.5M sold.

Sessa Capital first reported a position in RLAY in Q1 2022 and held it in 4 quarters. The position peaked at $9.02M in Q1 2022. 157 funds tracked by Wall St. Rank hold RLAY as of Q1 2023.

  • Sessa Capital reported no remaining Relay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sessa Capital sold 301,200 Relay Therapeutics shares in Q1 2023, an estimated $4.5M.
  • Sessa Capital first reported a position in Relay Therapeutics in Q1 2022 and held it in 4 quarters.
  • Sessa Capital's Relay Therapeutics position peaked at $9.02M in Q1 2022.
  • 157 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2023.

Based on Sessa Capital's 13F filing for Q1 2023, filed 15 May 2023.